{"schema_version":"secwatch.filing_event.v1","accession":"0001093557-26-000142","form_type":"8-K","ticker":"DXCM","cik":"0001093557","company_name":"DEXCOM INC","filed_at":"2026-07-30T20:03:41+00:00","discovered_at":"2026-07-30T20:05:00.730676+00:00","generated_at":"2026-07-30T20:05:15.323506+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"DexCom Q2 2026 revenue up 13% to $1.308B; raises FY2026 guidance","bullets":["Revenue $1.308B (+13% YoY); U.S. +11%, international +19% reported.","GAAP EPS $0.64; non-GAAP EPS $0.70; GAAP operating margin 24.3% (+590 bps YoY).","Raises FY2026 revenue guidance to $5.18-5.25B (11-13% growth); raises non-GAAP operating margin to ~23.5-24%.","CONNECT trial shows CGM improves glucose control in type 2 diabetes not on insulin; Stelo app launched with AI insights.","Cash $1.95B; revolving credit undrawn."],"urls":{"canonical":"https://secwatch.observer/filing/0001093557-26-000142","json":"https://secwatch.observer/filing/0001093557-26-000142.json","markdown":"https://secwatch.observer/filing/0001093557-26-000142.md","text":"https://secwatch.observer/filing/0001093557-26-000142.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1093557/000109355726000142/0001093557-26-000142-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1093557/000109355726000142/dxcm-20260730.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-30T20:05:15.323506+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}